Pneumonia

>

Latest News

FDA Approves Merck's 21-Valent Pneumococcal Vaccine for Adults 50 Years of Age and Older: A First and Long-Awaited
FDA Approves Merck's 21-Valent Pneumococcal Vaccine for Adults 50 Years of Age and Older: A First and Long-Awaited

June 18th 2024

Capvaxive is the only pneumococcal vaccine formulated specifically to protect adults 50 years and older from IPD and elicited robust immune responses in both vaccine-naïve and vaccine-experienced adults.

Older, Mentally Altered Adults at Greatest Risk for Inappropriate Diagnosis of CAP
Older, Mentally Altered Adults at Greatest Risk for Inappropriate Diagnosis of CAP

April 5th 2024

©Kateryna_Kon/stock.adobe.com
Merck's 21-Valent Adult-Specific Pneumococcal Vaccine Accrues New Phase 3 and Real World Data

March 19th 2024

FDA Grants Priority Review to Merck BLA for Investigational 21-Valent Pneumococcal Vaccine December 19, 2023
FDA Grants Priority Review to Merck BLA for Investigational 21-Valent Pneumococcal Vaccine

December 19th 2023

Hydrocortisone Bests Other Corticosteroids for Community-Acquired Pneumonia in New Analysis / Image credit: ©Crystal Light/AdobeStock
Hydrocortisone Bests Other Corticosteroids for Community-Acquired Pneumonia in New Analysis

October 23rd 2023

Video Interviews

More News

© 2024 MJH Life Sciences

All rights reserved.